Objective: To determine the cost-effectiveness and safety of a set of rational use guidelines for analgesia, sedation, and neuromuscular blockade in critically ill ventilated patients when compared with similar factors in standard prescribing.
I ncreased use of technology in the management of critical illness has resulted in the provision of complex pharmacotherapeutic regimens to enhance patient care (1) (2) (3) (4) . To this end, critical care physicians are often called on to prescribe analgesics, sedatives, and neuromuscular junction blockers (NMJBs). Indications for these drugs include pain control, anxiolysis, manage-ment of drug withdrawal syndromes, treatment of seizures, and facilitation of mechanical ventilation. Most patients admitted to the intensive care unit (ICU) and virtually all mechanically ventilated patients will require some form of this pharmacotherapy. Proper use can enhance patient comfort and safety, but misuse, side effects, and adverse reactions to these drugs are common and costly (5) (6) (7) (8) (9) . The challenge for critical care physicians regarding the use of analgesics, sedatives, and NMJBs is to provide comfort and safety without increased cost, morbidity, and mortality. Because of the potential high cost of these drugs and the frequency and cost of associated complications, physicians have been forced to reexamine their use and to search for optimal prescribing patterns that improve patient outcome (8, 10 -13) . The potential for misuse and adverse outcomes is so great that detailed reports of complications are common in the litera-ture (14) . Reports include use patterns, costs of use, and adverse outcomes (15, 16) . In these reports, inappropriate use (17) , high costs (6, 7, 12, 18 -20) , and adverse outcomes (5, (21) (22) (23) have been well documented. However, the documentation of the frequency and severity of adverse events and improved use and outcome has been limited (24, 25) . Our goal was to document reduced cost without adverse outcome.
Assessments of appropriate use to date include literature on surveys (26 -28) , data on the adverse effects (21) (22) (23) , and the impact of guidelines on cost reduction (18, 29 -31) . Few studies have prospectively examined the pharmacoeconomic impact of guidelines on cost and outcome (32) (33) (34) . Although some authors have attempted to quantify the impact of guidelines (18) , none has done so in a comprehensive, systematic manner. We hypothesized that proper use of these drugs can result in enhanced patient comfort and safety, as well as reduced cost and improved outcome. Our objective was to prospectively determine the cost effectiveness and safety of instituting rational use guidelines for analgesia, sedation, and NMJBs as compared with those factors in standard prescribing.
MATERIALS AND METHODS
After Institutional Review Board for the Protection of Human Subjects approval and waiver of informed consent, prospective data collection occurred in two phases. Data from the phase 1 (baseline) group of patients were collected from March 3, 1995 , to September 15, 1995 , before the implementation of guidelines, which were instituted on February 1, 1996. The data from the phase 2 (follow-up) group of patients were collected from June 18, 1996 , to September 22, 1996 . Phase 1 (baseline) involved data collection regarding all ICU patients who required continuous analgesics, sedatives, and/or NMJBs. Those patients who received scheduled intravenous doses and those who received continuous infusions were included. Data collected included date, age, gender, weight, Acute Physiology and Chronic Health Evaluation (APACHE) II scores (35) , prescriber, date admitted, date admitted to the ICU, date and time intubated, date and time extubated, diagnosis, indication for drug treatment, serum creatinine level, duration of treatment, daily mean acquisition drug cost of therapy per 24 hrs, maximum acquisition drug cost in 24 hrs, monitoring variables, and functional status at discharge. Functional status was recorded so that the potential longterm impact of the guidelines on the patient's discharge status (and in particular, prolonged weakness from NMJBs) could be considered. An assessment of daily living variables was used to classify discharged patients into one of the following functional status categories: alive/full function, alive/rehabilitation, alive/ disability, or dead.
During the baseline data collection, academic detailing (see below) was not performed, and intervention on optimization of therapy was minimal. Simultaneously, guidelines (36) were developed, subjected to multidisciplinary review, agreed on, and distributed in a handbook to all potential prescribers. Data from the baseline group of patients were used to establish the lowest cost drug regimens in surviving patients. The guidelines emphasized rational, cost-effective use of these drugs in critically ill ventilator-dependent patients. The guidelines provided a series of considerations for the prescriber, including assessment of need; prescribing; dosing; adjusting; monitoring; and weaning the patient from analgesics, sedatives, and NMJBs ( Fig. 1 ). Additionally, therapeutic end points were agreed on. Single scoring systems for end points of analgesia, sedation, and NMJBs were defined. These guidelines also described an aggressive, systematic, stepped approach to the treatment of each patient by maximizing the effectiveness of regimens in the following order: analgesics, then sedatives, and finally, if necessary, NMJBs. Each class of drug efficacy was maximized by means of monitoring and rapid end point dosage adjustment before progression to the next class or type of therapy. End points were designated as follows: for analgesia, reduction in pain to a tolerable level; for sedation, a calm, cooperative patient, despite ICU stress; and for neuromuscular blockade, a sufficient dose to enable adequate mechanical ventilation. It should be stressed that analgesic and sedative doses were rapidly increased, if necessary, to facilitate mechanical ventilation before NMJBs were added. Algorithms were used to facilitate decision making in drug choice and usage and dosage adjustment (Figs. [2] [3] [4] . Compliance with the guidelines was extremely high because weekly meetings of the attending medical staff directors occurred, which facilitated discussing specific instances of compliance and deviation.
An academic detailing process was used to educate practitioners about the use of guidelines. This process involved prospective pharmacotherapy regimen review by a clinical pharmacist or an anesthesiology critical care consultant. Daily interventions were performed, and the prescribers were made aware by direct and written communication when their regimens varied from the suggested guidelines. The cost implications of such deviations were also brought to the attention of the prescribers. Additionally, posters were placed in the ICUs to reinforce the information, bedside nurses were educated about the guidelines, and a poster copy was placed at each bedside. After 4 months of academic detailing, phase 2 (follow-up) data were collected. Follow-up data collection duplicated that of the baseline group. To verify that our data were not skewed by a population of patients with a traditionally extended length of stay, we studied a subgroup of patients with tracheostomy and prolonged ventilation (diagnosis-related group [DRG] 483) to examine the impact on the data from this critically ill subgroup comparison.
Demographic variables of baseline and follow-up groups were compared via an unpaired Student's t-test for continuous variables. The chi-square test was used as a nonparametric test for the comparison of mortality and to determine the frequency of NMJB use. A p Ͻ .05 was considered statistically significant. 
RESULTS
Both the baseline and follow-up groups were similar with regard to number of regimens, days of treatment, gender, and age. APACHE II scores in the follow-up group were significantly higher than those at baseline. Additionally, the frequency for use of NMJBs was significantly less in the follow-up group (Table  1) . Ventilator time and lengths of stay were less in the follow-up group without a significant increase in mortality ( Table  2) .
Drug costs were significantly reduced in the follow-up group (Table 3) . Mean drug costs were reduced across all classes; the largest percent of reduction was noted in NMJBs. The maximal drug cost per day was reduced in all categories for the follow-up group, except when propofol was used for Ͻ24 hours. The largest percent reduction in the maximal cost per day was with NMJBs.
There was a very high mortality rate in patients who received NMJBs in both the baseline and follow-up groups. In those groups, eight of 22 baseline patients (36.4%) and two of four (50%) of the follow-up patients died. Similar outcomes were found when DRG 483 was compared with the entire cohort. However, no significant change in length of stay or ICU length of stay was realized in DRG 483 ( Table 4 ).
The functional status data appeared to indicate an improvement in outcomes in the follow-up group. There was a reduction in the number of patients who required rehabilitation in the follow-up group when compared with that number in the baseline group (Table 5 ).
DISCUSSION
In our research, guidelines used a fivestep process that included evaluation, analgesia, sedation, neuromuscular junction blockade, and dosage adjustment and preserved a distinct end point for each class of agents. This is the first comprehensive prospective study that has documented safe cost reductions via the use of guidelines for analgesia, sedation, and NMJBs in critically ill patients. We were able to accomplish significant cost reductions in the provision of these drugs to ventilated patients in the ICU without compromising quality of care. We have documented that the cost reductions are attributable to the institution of the guidelines and that the guidelines enabled reductions in ventilator time and ICU length of stay. Furthermore, we observed a dramatic decrease in the frequency of NMJB use, which was an unexpected but not surprising finding in a population given optimal analgesic and sedative doses before institution of NMJBs is considered. There were no documented cases of prolonged weakness in the follow-up group, despite the preferential use of pancuronium bromide in these patients. To further validate our findings, the subgroup DRG 483 was compared before and after guidelines. Comparison of these groups verified safe cost reductions in this critically ill population.
A review of the literature revealed two publications regarding the impact of guidelines for analgesia, sedation, and/or NJMB (18, 29) . The first, by Tschida et al. (29) , studied the impact of practice guidelines on prescribing patterns of NMJBs. These authors developed and im-plemented neuromuscular junction blockade guidelines with an interdisciplinary ICU team. They used a decision tree to optimize pharmacotherapy that was based on each patient's end-organ function. A series of 24 patients was examined in the baseline group, and 23 patients were examined in the follow-up group. The authors' 12-month retrospective review documented a dramatic reduction of inappropriate prescribing. They found a decrease (80% to 25%) in the prevalence of inappropriate NMJB selection after institution of their guidelines. Pharmacoeconomic analysis (costs, outcomes, and length of stay) was not performed.
Devlin et al. (18) considered the effect of ICU sedation guidelines and pharmacist interventions on clinical outcomes and costs. The objective of their study was to measure the effect of evidencebased ICU sedation guidelines and interventions on weaning time and sedation drug cost. Two consecutive groups of 50 mechanically ventilated ICU survivors were studied. The authors' guidelines were developed via physician, nurse, and pharmacist consensus. They collected data on the time required to wean pa-tients from mechanical ventilation and on mean and total drug costs. Over the 2-month data collection period, they found no significant difference in median weaning time, even though patients in the follow-up group had significantly higher APACHE II scores. Total sedation costs were reduced from $4,515 to $1,152 (p ϭ .081). Mean sedation costs were reduced from $81.54 to $18.12 per day.
The limitations of our study resulted predominantly from the inability to control the large number of variables inherent in the care of critically ill patients. Specifically, it would be preferable to study matched pairs of patients with similar pathologic conditions and severity of illness and then to randomize those patients into a guideline or a no-guideline group that would be tracked simultaneously. Although this might be the ideal method, it too is limited by the effect of intervention on data collection, because it is virtually impossible to blind such a study. Our baseline data provided information with minimal provider awareness. This is a major advantage of the "baseline, follow-up" approach. Another option would be to examine the impact of compliance vs. noncompliance with guidelines on cost and outcome. This strategy, although also not ideal, could use the group with provider noncompliance as a control. In addition, compliance can be quantified and qualitatively measured. The major advantage of this approach (compliance vs. noncompliance) is that it may provide the best practical measure of guidelines on cost and outcome because it can be combined with a provider feedback system.
Because the nature of critical care makes it extremely difficult to conduct blinded, controlled, clinical trials of stepped drug protocols, we believe our efforts to date represent the best available information on the subject. In addition to the issues raised above, although we col- lected data on a daily and prospective basis, the interactions and education with the prescribers did not occur immediately. This problem forced frequent changes in orders that had already been initiated. Furthermore, conclusions regarding adverse drug reactions were also limited by the multitude of concomitant diseases that produce symptoms similar to those caused by adverse drug events. Adverse effect assessment was also based on clinical and functional assessment rather than a comprehensive work-up (for example muscle biopsy, nerve conduction studies, and levels of NMJBs for the assessment of prolonged weakness) for the determination of cause-and-effect relationships. This issue, however, is not a key point of this study. A final limitation in this study was the lack of blinding of the clinical research nurse collecting data. Despite these constraints, the information obtained is relevant, useful, and significant.
CONCLUSIONS
Our study demonstrates that the use of a set of rational guidelines for analgesia, sedation, and NMJBs is safe and effective. Furthermore, guidelines can reduce the need for NMJBs, reduce drug costs, and improve outcomes when compared with those factors in normal prescribing. Previously published data are limited but are consistent with our findings. Our study is the first to demonstrate these findings in a comprehensive manner. Further pharmacoeconomic research is needed to determine the impact of guidelines on other pharmacotherapeutic agents commonly used in the critical care setting. 
